Modified pectins, compositions and methods related thereto
View Patent ↗The present invention provides compositions of modified pectin and methods for preparing and using them.
1. A method of treating chronic inflammation in a patient in need thereof, comprising administering to the patient a liquid composition comprising colloidal particles of a purified modified pectin or a purified, deesterified, and partially depolymerized modified pectin, wherein the colloidal particles of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin consist essentially of colloidal particles which are less than 1 micron in diameter and the composition is substantially free of modified pectins having molecular weights below 25 kD.
2. The method of claim 1 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-150 kD.
3. The method of claim 2 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-100 kD.
4. The method of claim 1 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 50-200 kD.
5. The method of claim 4 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 70-150 kD.
6. The method of claim 1 , wherein the composition is an aqueous solution.
7. The method of claim 6 , wherein the solution contains at least 0.5% by weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin.
8. The method of claim 7 , wherein the solution contains at least 5% by weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin.
9. The method of claim 1 , wherein the composition is a colloidal suspension.
10. The method of claim 1 , wherein the colloidal particles are less than 0.20 μm in diameter.
11. The method of claim 1 , wherein the composition comprises a purified modified pectin.
12. The method of claim 1 , wherein the composition comprises a purified, deesterified, and partially depolymerized modified pectin.
13. The method of claim 1 , wherein the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin inhibits cancer proliferation with an IC 50 less than 200 μg/mL.
14. The method of claim 13 , wherein the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin inhibits cancer proliferation with an IC 50 in the range of 25-75 μg/mL.
15. The method of claim 1 , wherein the composition is a dosage form selected from dosage forms suitable for oral dosage, topical application, and inhalation.
16. The method of claim 15 , wherein the dosage form is suitable for oral dosage.
17. The method of claim 1 , wherein the composition is a dosage form suitable for parenteral administration.
18. The method of claim 17 , wherein the parenteral administration is selected from injection or intravenous infusion.
19. The method of claim 1 , wherein the composition is a colloidal solution.
20. A method of treating chronic inflammation in a patient in need thereof, comprising administering to the patient a liquid composition comprising colloidal particles of a purified modified pectin or a purified, deesterified, and partially depolymerized modified pectin, wherein the colloidal particles of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin consist essentially of colloidal particles which are less than 1 micron in diameter and the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 70-150 kD.
21. The method of claim 20 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-150 kD.
22. The method of claim 21 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-100 kD.
23. The method of claim 20 , wherein the composition is an aqueous solution.
24. The method of claim 23 , wherein the solution contains at least 0.5% by weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin.
25. The method of claim 24 , wherein the solution contains at least 5% by weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin.
26. The method of claim 23 , wherein the composition is a colloidal solution.
27. The method of claim 20 , wherein the composition is a colloidal suspension.
28. The method of claim 20 , wherein the colloidal particles are less than 0.20 μm in diameter.
29. The method of claim 20 , wherein the composition comprises a purified modified pectin.
30. The method of claim 20 , wherein the composition comprises a purified, deesterified, and partially depolymerized modified pectin.
31. The method of claim 20 , wherein the composition is a dosage form selected from dosage forms suitable for oral dosage, topical application, and inhalation.
32. The method of claim 31 , wherein the dosage form is suitable for oral dosage.
33. The method of claim 20 , wherein the composition is a dosage form suitable for parenteral administration.
34. The method of claim 33 , wherein the parenteral administration is selected from injection or intravenous infusion.